PT  - JOURNAL ARTICLE
AU  - U S Rao
AU  - G A Scarborough
TI  - Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein.
DP  - 1994 Apr 01
TA  - Molecular Pharmacology
PG  - 773--776
VI  - 45
IP  - 4
4099  - http://molpharm.aspetjournals.org/content/45/4/773.short
4100  - http://molpharm.aspetjournals.org/content/45/4/773.full
SO  - Mol Pharmacol1994 Apr 01; 45
AB  - The interactions between the human P-glycoprotein (Pgp) and two different types of immunosuppressant drugs known to modulate multidrug resistance in tumor cells have been directly investigated using our newly developed drug-stimulated ATPase assay for Pgp function. The macrolides FK506 and FK520 stimulate the Pgp-ATPase activity with affinities in the 100 nM range, nearly 10 times higher than that of verapamil, a well known Pgp substrate. On the other hand, the cyclic peptides cyclosporin A and dihydrocyclosporin C do not stimulate the Pgp-ATPase activity at all. They do, however, act as potent competitive inhibitors of verapamil-stimulated Pgp-ATPase activity, with affinity constants in the 20-25 nM range. Thus, although these two classes of immunosuppressant drugs affect the Pgp in different ways, they both probably interact with high affinity at the transported drug binding site(s) of the Pgp, which would explain their ability to resensitize multidrug-resistant cells to the killing action of certain antitumor drugs. Possible implications of these findings for Pgp function, cancer chemotherapy, and immunosuppression are discussed.